ASX:BXN

Bioxyne Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume174,489 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive BXN News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioxyne and its competitors with MarketBeat's FREE daily newsletter.


About Bioxyne

Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. The company operates in two segments, Wholesale Sales and Direct Sales segments. It also engages in developing a range of functional foods and beauty products. The company's products portfolio include BK18, a dairy based food supplement; Allura, a beauty drink for women's weight management; Mustang, a nutritional shake for men's weight management; Mymana, a colostrum and fortified milk formula for nutrition and immune support; and BEssence, an anti-ageing serum. In addition, it offers its probiotic products under the Progastrim and proTract names. The company provides its products online, as well as through retail channels in Australia, the United States, New Zealand, and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bioxyne (ASX:BXN) Frequently Asked Questions

What stocks does MarketBeat like better than Bioxyne?

Wall Street analysts have given Bioxyne a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bioxyne wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Bioxyne's key executives?

Bioxyne's management team includes the following people:
  • Mr. Nam Hoat Chua B.A., BA, MD, CEO & Director
  • Mr. Guy Adrian Robertson B.Com., C.A., B.Comm(Hons.), CA, MAICD, CFO & Company Sec.

Who are some of Bioxyne's key competitors?

What is Bioxyne's stock symbol?

Bioxyne trades on the ASX under the ticker symbol "BXN."

How much money does Bioxyne make?

Bioxyne has a market capitalization of $0.00 and generates $2.20 million in revenue each year.

What is Bioxyne's official website?

The official website for Bioxyne is www.bioxyne.com.

How can I contact Bioxyne?

The company can be reached via phone at 61 2 9078 8180.


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.